🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the effort against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are on the rise worldwide, with figures suggesting over 82 million new cases per year. Especially elevated rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the context of rising global incidence, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Public health authorities are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has classified it as a "critical concern". A tracking program showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Secure Authorization

One new antibiotic, also known as Nuzolvence, was approved by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers anticipate that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, gained clearance in the same week. This medication, which is employed against urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This authorization represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Research Study Outcomes and Global Access

As per findings released by a major medical journal, zoliflodacin successfully treated over nine in ten of cases of the STI. This puts it on an comparable level with the existing first-line therapy, which uses two antibiotics. The research enrolled over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to make available and distribute the drug in numerous regions with limited resources.

Clinicians treating patients have expressed hope. Having a one-pill regimen of this kind is seen as a "critical tool" for gonorrhoea control. This is deemed vital to reduce the burden of the illness for individuals and to halt the transmission of extremely resistant gonorrhoea globally.